Compounds used as PARP inhibitors
By developing compounds of formula (I) to inhibit PARP enzymes, the shortcomings in the treatment of cancer and inflammatory diseases in the prior art are solved, and effective treatment of a variety of cancer and inflammatory diseases is achieved, especially by using in combination with other therapeutic methods to enhance the efficacy.
Patent Information
- Application Number
- CN202180030479.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-11-02
- Filing Date
- 2021-04-23
- Publication Date
- 2025-07-15
- Estimated Expiration
- 2041-04-23
AI Technical Summary
Existing PARP inhibitors have not yet met the need to treat various diseases and disorders associated with cell proliferation, especially cancer, and available clinical data show that PARP activation is associated with indications such as stroke, traumatic brain injury, circulating shock and acute myocardial infarction.
A compound of formula (I) and a pharmaceutically acceptable salt thereof are developed to treat diseases or disorders associated with PARP, including cancer, inflammatory diseases, autoimmune diseases, etc., by inhibiting the PARP enzyme, including cancer, inflammatory diseases, autoimmune diseases, etc., including administration of an effective amount of the compound alone or in combination with other anti-inflammatory agents, immunomodulatory agents and anti-cancer agents.
Effectively inhibit PARP enzyme, reduce cell proliferation, treat a variety of cancers and inflammatory diseases, including bladder cancer, breast cancer, colon cancer, kidney cancer, etc., and can be used in combination with other treatment methods to enhance the efficacy.